Should I Take Wegovy? Honest Answers Before You Commit

Do I actually meet the criteria Wegovy is licensed for?

This is the first thing a prescriber will look at. The UK licence covers adults with a BMI of 30 or above, or 27 to 29.9 when at least one weight-related condition is present, for example, high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, a detail worth raising in your consultation if relevant to you.

BMI on its own tells a prescriber relatively little. They will also look at your current medicines, any history of pancreatitis, thyroid conditions or kidney disease, and how realistic sustained lifestyle changes are alongside treatment. The NHS semaglutide page sets out the main contraindications clearly if you want to read them before your appointment.

One practical habit worth building now: check the weight-related conditions list against your own medical records or GP summary. If you have a diagnosed condition that qualifies you at a lower BMI, noting it before your consultation speeds things up. It takes about 30 seconds and makes the clinical conversation more focused.

If you are on the NHS, NICE's recommendations under TA875 set stricter thresholds for funded access, including use within a specialist weight management service for a maximum of two years. Private treatment through a regulated pharmacy follows the licensed eligibility criteria directly, with no waiting list.

What does taking Wegovy actually involve day to day?

The honest answer is that it asks something of you. The injection itself is straightforward, a small pre-filled pen, once a week, into the abdomen, thigh or upper arm. Most people settle into a routine quickly. Thinking about when to take Wegovy each week matters more than most realise; picking a consistent day and time makes it easier to stick to and helps your prescriber track your response.

The titration schedule runs from 0.25 mg up through 0.5 mg, 1.0 mg and 1.7 mg to 2.4 mg maintenance, with roughly a month at each level. A higher 7.2 mg maintenance dose received MHRA approval in early 2026 and may be discussed with your prescriber once established on lower doses. The purpose of stepping up slowly is reducing gastrointestinal side effects, nausea, loose stools and indigestion are common early on and generally settle as your body adjusts.

Alongside the medicine, the clinical expectation is a reduced-calorie diet and more physical activity. These are not optional extras. Trial evidence and the licence both frame Wegovy as an adjunct to lifestyle change, not a standalone fix. If you are asking yourself whether taking Wegovy for weight loss is the right route, it helps to be honest about what support you have around the food and movement side of things too.

Storage requires a fridge (2–8°C), once you have opened or started a pen, refer to the Patient Information Leaflet for the exact room-temperature window permitted, since this varies.

What are the realistic side effects, and when should I get medical help?

Most people experience some gastrointestinal effects, especially in the first few weeks after starting or stepping up a dose. Nausea is the most frequently reported; vomiting, constipation, diarrhoea and reflux are also common. They tend to ease once the body acclimates. Eating smaller portions and avoiding fatty or heavily spiced food during the early weeks helps many people.

Less common but important: the MHRA issued a Drug Safety Update in January 2026 drawing prescribers' and patients' attention to acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines. Severe abdominal pain (especially pain that spreads to the back and does not settle) warrants urgent medical attention, not a wait-and-see approach. Gallbladder problems have also been reported in clinical trials.

You can report any suspected side effect using the MHRA's Yellow Card scheme, it exists precisely so that real-world safety signals get captured, and patients can use it directly.

A question our prescribers hear often: does being nervous about injections count as a reason not to start? Not really, the needle is fine-gauge and pre-set, and the mechanism is designed to be simple. Hesitation about self-injecting is common and worth naming at your consultation, where the technique can be talked through properly. There is also a practical question about evening versus morning dosing that some people find relevant to managing nausea.

Should I go ahead, and what happens if I decide yes?

That is genuinely a clinical decision, made with a prescriber who can read your full picture. What this page can tell you is that for people who meet the eligibility criteria and have no contraindications, the evidence base for semaglutide is substantial, the STEP 1 trial involved nearly 2,000 adults over 68 weeks, and the 15% average weight reduction at 2.4 mg is among the strongest results seen for a licensed weight-loss medicine in the UK prior to tirzepatide. You can read more about how Wegovy works and what to expect before making up your mind.

If you are also weighing up cost as part of the decision, a look at where to get Wegovy in the UK gives a factual overview of the private route versus NHS access, including what an honest price comparison should include. The weight loss treatment overview covers the options side by side if you want a broader frame before committing.

At nume, consultations are reviewed the same day by a GPhC-registered Independent Prescriber. Your answers are read by a real clinician, not software, and approval only follows if treatment is genuinely suitable for you. If you are ready to find out where you stand, checking your eligibility takes only a few minutes and costs nothing.